Home LiteratureArticle Details
PMID: 9245797 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

The Journal of cell biology ·Vol. 138 ·No. 3 ·1997-08-11 ·Pages 707-17

Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP

Abstract

Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that is able to make normal endothelial cells unresponsive to a wide variety of inducers. Here we use both native TSP-1 and small antiangiogenic peptides derived from it to show that this inhibition is mediated by CD36, a transmembrane glycoprotein found on microvascular endothelial cells. Both IgG antibodies against CD36 and glutathione-S-transferase-CD36 fusion proteins that contain the TSP-1 binding site blocked the ability of intact TSP-1 and its active peptides to inhibit the migration of cultured microvascular endothelial cells. In addition, antiangiogenic TSP-1 peptides inhibited the binding of native TSP-1 to solid phase CD36 and its fusion proteins, as well as to CD36-expressing cells. Additional molecules known to bind CD36, including the IgM anti-CD36 antibody SM, oxidized (but not unoxidized) low density lipoprotein, and human collagen 1, mimicked TSP-1 by inhibiting the migration of human microvascular endothelial cells. Transfection of CD36-deficient human umbilical vein endothelial cells with a CD36 expression plasmid caused them to become sensitive to TSP-1 inhibition of their migration and tube formation. This work demonstrates that endothelial CD36, previously thought to be involved only in adhesion and scavenging activities, may be essential for the inhibition of angiogenesis by thrombospondin-1.

MeSH Terms
Amino Acid Sequence Animals CD36 Antigens/genetics,immunology,metabolism,physiology Cattle Cell Movement/drug effects Cells, Cultured Endothelium, Vascular/drug effects,physiology Humans Ligands Membrane Glycoproteins/metabolism,pharmacology Molecular Sequence Data Neovascularization, Physiologic/drug effects Peptide Fragments/metabolism,pharmacology Recombinant Fusion Proteins/pharmacology Thrombospondins Transfection
Chemicals
CD36 Antigens Ligands Membrane Glycoproteins Peptide Fragments Recombinant Fusion Proteins Thrombospondins
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Dawson D W
Department of Microbiology-Immunology and Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Pearce S F
Zhong R
Silverstein R L
Frazier W A
Bouck N P
References (73)
73 references, click to expand
  1. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.
    Am J Hematol. 1996 Apr;51(4):296-301 PMID: 8602630
  2. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3497-502 PMID: 8622965
  3. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36.
    J Biol Chem. 1996 Aug 23;271(34):20536-9 PMID: 8702796
  4. Scatter factor binds to thrombospondin and other extracellular matrix components.
    Am J Pathol. 1996 Sep;149(3):805-19 PMID: 8780385
  5. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response.
    Am J Pathol. 1996 Sep;149(3):911-21 PMID: 8780395
  6. How tumors become angiogenic.
    Adv Cancer Res. 1996;69:135-74 PMID: 8791681
  7. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn.
    J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 PMID: 8832401
  8. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium.
    J Cell Sci. 1996 Feb;109 ( Pt 2):387-95 PMID: 8838662
  9. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation.
    Mol Biol Cell. 1996 Aug;7(8):1209-24 PMID: 8856665
  10. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
    Cancer Res. 1996 Nov 1;56(21):4887-90 PMID: 8895739
  11. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.
    Cancer Res. 1996 Dec 15;56(24):5684-91 PMID: 8971176
  12. Involvement of protein tyrosine kinases in regulation of endothelial cell organization by basement membrane proteins.
    Biochem Biophys Res Commun. 1996 Dec 13;229(2):375-80 PMID: 8954907
  13. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP?
    Cell. 1996 Dec 13;87(6):961-4 PMID: 8978600
  14. Apoptosis by death factor.
    Cell. 1997 Feb 7;88(3):355-65 PMID: 9039262
  15. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts.
    Eur J Cancer. 1996 Dec;32A(14):2394-400 PMID: 9059327
  16. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity.
    Oncogene. 1997 Mar 27;14(12):1495-502 PMID: 9136993
  17. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
    Invest New Drugs. 1997;15(1):49-59 PMID: 9195289
  18. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1.
    Microvasc Res. 1997 Jul;54(1):13-26 PMID: 9245640
  19. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets.
    Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7844-8 PMID: 1715582
  20. Thrombospondins.
    Curr Opin Cell Biol. 1991 Oct;3(5):792-9 PMID: 1718338
  21. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro.
    J Immunol. 1992 Jan 1;148(1):78-83 PMID: 1370173
  22. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding.
    Biochem Biophys Res Commun. 1992 Feb 14;182(3):1208-17 PMID: 1371676
  23. Human platelet glycoprotein IIIb binds to thrombospondin fragments bearing the C-terminal region, and/or the type I repeats (CSVTCG motif), but not to the N-terminal heparin-binding region.
    Biochem J. 1992 May 15;284 ( Pt 1):231-6 PMID: 1376110
  24. Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor.
    J Biol Chem. 1992 Aug 15;267(23):16607-12 PMID: 1379600
  25. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine.
    Blood. 1992 Sep 1;80(5):1105-15 PMID: 1381234
  26. CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction.
    J Biol Chem. 1992 Sep 5;267(25):18244-50 PMID: 1381367
  27. Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis.
    J Biol Chem. 1992 Sep 25;267(27):19349-55 PMID: 1527055
  28. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis.
    J Clin Invest. 1992 Oct;90(4):1513-22 PMID: 1383273
  29. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.
    J Cell Biol. 1993 Jan;120(2):513-21 PMID: 8421063
  30. CD36 is a receptor for oxidized low density lipoprotein.
    J Biol Chem. 1993 Jun 5;268(16):11811-6 PMID: 7685021
  31. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.
    J Cell Biol. 1993 Jul;122(2):497-511 PMID: 7686555
  32. Identification of SVTCG in thrombospondin as the conformation-dependent, high affinity binding site for its receptor, CD36.
    J Biol Chem. 1993 Aug 5;268(22):16179-84 PMID: 7688364
  33. The functions of thrombospondin and its involvement in physiology and pathophysiology.
    Biochim Biophys Acta. 1993 Aug 4;1182(1):1-14 PMID: 8347680
  34. Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture.
    J Immunol. 1993 Nov 1;151(9):5062-72 PMID: 7691964
  35. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin.
    J Cell Biochem. 1993 Sep;53(1):74-84 PMID: 8227183
  36. Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain.
    Science. 1993 Nov 26;262(5138):1436-40 PMID: 7504322
  37. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
    J Immunol. 1994 Apr 15;152(8):4149-56 PMID: 7511670
  38. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis.
    J Vasc Res. 1994 May-Jun;31(3):178-85 PMID: 7511943
  39. Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta.
    J Cell Sci. 1994 Jan;107 ( Pt 1):39-46 PMID: 8175921
  40. Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells.
    FEBS Lett. 1994 Aug 29;351(1):41-4 PMID: 7521304
  41. Use of a radioimmunoassay to quantify thrombospondin.
    Blood. 1982 Jan;59(1):162-6 PMID: 7053762
  42. A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers.
    Thromb Res. 1983 Mar 15;29(6):569-81 PMID: 6190242
  43. Angiogenic factors.
    Science. 1987 Jan 23;235(4787):442-7 PMID: 2432664
  44. Isolation of the thrombospondin membrane receptor.
    J Clin Invest. 1987 Apr;79(4):1054-61 PMID: 2435757
  45. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.
    Cell. 1989 Feb 10;56(3):345-55 PMID: 2464438
  46. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion.
    J Biol Chem. 1989 May 5;264(13):7576-83 PMID: 2468670
  47. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes.
    Cell. 1989 Jul 14;58(1):95-101 PMID: 2473841
  48. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro.
    J Clin Invest. 1989 Aug;84(2):468-75 PMID: 2474569
  49. Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor.
    Biochem J. 1989 Sep 15;262(3):835-42 PMID: 2480109
  50. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.
    J Cell Biol. 1990 Aug;111(2):765-72 PMID: 1696271
  51. Specific inhibition of endothelial cell proliferation by thrombospondin.
    Biochem Biophys Res Commun. 1990 Jul 31;170(2):867-72 PMID: 1696478
  52. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8 PMID: 1697685
  53. Regulators of angiogenesis.
    Annu Rev Physiol. 1991;53:217-39 PMID: 1710435
  54. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5026-30 PMID: 1711216
  55. Human carcinoma cells bind thrombospondin through a Mr 80,000/105,000 receptor.
    Cancer Res. 1991 Jul 15;51(14):3648-56 PMID: 1712244
  56. Assay and purification of naturally occurring inhibitor of angiogenesis.
    Methods Enzymol. 1991;198:440-50 PMID: 1857235
  57. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.
    Science. 1994 Sep 9;265(5178):1582-4 PMID: 7521539
  58. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
    Cell. 1994 Oct 21;79(2):315-28 PMID: 7525077
  59. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.
    Cancer Res. 1994 Dec 15;54(24):6504-11 PMID: 7527299
  60. Identification of an immunodominant functional domain on human CD36 antigen using human-mouse chimaeric proteins and homologue-replacement mutagenesis.
    Biochem J. 1995 Jan 1;305 ( Pt 1):221-4 PMID: 7529996
  61. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36.
    J Biol Chem. 1995 Feb 17;270(7):2981-6 PMID: 7531696
  62. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans.
    J Biol Chem. 1995 Apr 21;270(16):9543-9 PMID: 7721883
  63. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis.
    J Exp Med. 1995 May 1;181(5):1857-62 PMID: 7536797
  64. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site.
    Arterioscler Thromb Vasc Biol. 1995 Feb;15(2):269-75 PMID: 7538425
  65. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells.
    J Cell Sci. 1995 Feb;108 ( Pt 2):797-809 PMID: 7539439
  66. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1.
    J Cell Biol. 1995 Jun;129(5):1403-10 PMID: 7775583
  67. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids.
    J Biol Chem. 1995 Jul 7;270(27):16221-4 PMID: 7541795
  68. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1.
    J Cell Biol. 1995 Aug;130(3):503-6 PMID: 7542656
  69. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.
    J Clin Invest. 1995 Oct;96(4):1859-65 PMID: 7560077
  70. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.
    N Engl J Med. 1995 Dec 28;333(26):1757-63 PMID: 7491141
  71. Inhibition of angiogenesis by thrombospondin-2.
    Biochem Biophys Res Commun. 1995 Dec 5;217(1):326-32 PMID: 8526929
  72. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin.
    J Biol Chem. 1996 Jan 5;271(1):21-4 PMID: 8550562
  73. Human microvascular endothelial cells adhere to thrombospondin-1 via an RGD/CSVTCG domain independent mechanism.
    J Invest Dermatol. 1996 Feb;106(2):215-20 PMID: 8601718
Article Info
Journal
The Journal of cell biology
Abbr.
J Cell Biol
ISSN
0021-9525
Published
1997-08-11
Pages
707-17
Language
English
Region
United States
NLM ID
0375356
PMCID
PMC2141641
Subset
IM
Grants
NCI NIH HHS · CA65872 · United States
NCI NIH HHS · CA52750 · United States
NCI NIH HHS · CA64239 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com